Position in LLY
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$521,752
+$84,862 QoQ
Shares Held
435
-8.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#3,726
of 4,605 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026First Fiduciary Investment Counsel, Inc. holds $51,339,791 across 7 Drug Manufacturers - General names. LLY ranks #6 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
73,221 | $18,595,937 | |
| 2 | NVS |
Novartis AG
|
99,224 | $15,550,385 | |
| 3 | AMGN |
Amgen Inc
|
25,171 | $9,114,922 | |
| 4 | PFE |
Pfizer Inc
|
256,357 | $6,173,076 | |
| 5 | MRK |
Merck & Co., Inc.
|
7,118 | $914,663 | |
| 6 | LLY |
ELI LILLY & Co
This page
|
435 | $521,752 | |
| 7 | ABBV |
AbbVie Inc.
|
1,864 | $469,056 |
All Filings in LLY
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $521,752 | 435 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $436,890 | 475 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $537,340 | 500 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $381,500 | 500 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $389,765 | 500 | Shares | Sole | 2025-07-24 | |
| No filing history on record for this holder in this stock. | ||||||